This website is intended for US Healthcare Professionals.

AACR 2023

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

Presentation
Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer
LB Snyder et al.
Poster
Mechanisms of acquired resistance to ARV-471, a novel PROTAC® estrogen receptor degrader
J Teh et al.
Poster
Enhanced efficacy of ARV-471, a novel PROTAC® estrogen receptor degrader, in combination with targeted agents in estrogen receptor-positive (ER+) breast cancer models
J Teh et al.

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.